LCZ696 Entèmedyè CAS 1426129-50-1 Pite ≥98.0% (HPLC) ee ≥99.0% Faktori Segondè Pite
Pwovizyon komèsyal LCZ696 (CAS: 936623-90-4) Entèmedyè ki gen rapò:
(R)-tèt-butyl (1-([1,1-biphenyl]-4-yl)-3-hydroxypropan-2-yl) carbamate CAS: 1426129-50-1
(R,E)-5-(1,1'-biphenyl-4-yl)-4-((tèt-butoxicarbonyl)amino)-2-methylpent-2-enoic asid CAS: 1012341-48-8
(2R,4S)-5-(1,1'-biphenyl-4-yl)-4-((tèt-butoxicarbonyl)amino)-2-methylpentanoic asid CAS: 1012341-50-2
(2R,4S)-etil 5-(1,1'-biphenyl-4-yl)-4-amino-2-methylpentanoate HCl CAS: 149690-12-0
AHU-377 (sèl emikalsyòm) CAS: 1369773-39-6
AHU-377;Sacubitril CAS: 149709-62-6
LCZ696;Entresto;Melanj Sacubitril ak Valsartan CAS: 936623-90-4
| Non Chimik | (R)-tèt-Butil (1-([1,1-biphenyl]-4-yl)-3-hydroxypropan-2-yl) carbamate |
| Sinonim | LCZ696 Entèmedyè |
| Nimewo CAS | 1426129-50-1 |
| Nimewo CAT | RF-PI169 |
| Estati Stock | Nan stock, pwodiksyon echèl jiska dè santèn de kilogram |
| Fòmil molekilè | C20H25NO3 |
| Pwa molekilè | 327.42 |
| Mak | Ruifu Chimik |
| Atik | Espesifikasyon |
| Aparans | Poud blan pou blan |
| Pite / Metòd analiz | ≥98.0% (HPLC) |
| Enantiomeric Depase | ee: ≥99.0% |
| Imidite (KF) | ≤1.0% |
| Sibstans ki gen rapò A | ≤1.0% (RRT=0.5) A=(R)-3-([1,1'-biphenyl]-4-yl)-2-aminopropan-1-ol |
| Sibstans ki gen rapò B | ≤1.0% (RRT = 0.85) B = oksid trifenilfosfin |
| Lòt sibstans | ≤1.0% |
| Enpurte total | ≤2.0% |
| Tès Creole | Enterprise Standard |
| Itilizasyon | Entèmedyè LCZ696 (CAS: 936623-90-4) nan tretman HFrEF |
Pake: Boutèy, sak papye aliminyòm, tanbou katon, 25kg / tanbou, oswa selon kondisyon kliyan an.
Kondisyon Depo:Sere nan resipyan ki fèmen nan yon kote ki fre ak sèk;Pwoteje kont limyè, imidite ak ensèk nuizib.
Manifakti ak pite segondè ak bon jan kalite ki estab
Pwovizyon komèsyal LCZ696 (CAS: 936623-90-4) Entèmedyè ki gen rapò:
(R)-tèt-butyl (1-([1,1-biphenyl]-4-yl)-3-hydroxypropan-2-yl) carbamate CAS: 1426129-50-1
(R,E)-5-(1,1'-biphenyl-4-yl)-4-((tèt-butoxicarbonyl)amino)-2-methylpent-2-enoic asid CAS: 1012341-48-8
(2R,4S)-5-(1,1'-biphenyl-4-yl)-4-((tèt-butoxicarbonyl)amino)-2-methylpentanoic asid CAS: 1012341-50-2
(2R,4S)-etil 5-(1,1'-biphenyl-4-yl)-4-amino-2-methylpentanoate HCl CAS: 149690-12-0
AHU-377 (sèl emikalsyòm) CAS: 1369773-39-6
AHU-377;Sacubitril CAS: 149709-62-6
LCZ696;Entresto;Melanj Sacubitril ak Valsartan CAS: 936623-90-4
LCZ696 se yon dwòg eksperimantal devlope pa Novartis Pharmaceutical nan peyi Etazini pou tretman pasyan ki gen ensifizans kadyak ak Fraksyon Ejection redwi (HFrEF).Ensifizans kadyak se yon maladi ki menase lavi.Kè pasyan an pa ka ponpe ase san pou bay kò a, epi parèt sentòm yo nan dispne, fatig ak likid retansyon dousman, Lè sa a, piti piti ogmante, siyifikativman afekte kalite lavi a.LCZ696 ka amelyore defans natirèl kò a kont ensifizans kadyak, osi byen ke ogmante nivo nan peptides natriuretic ak lòt peptides vazoaktif andojèn, ak anpeche sistèm renin-angiotensin-aldosterone (RAAS).LCZ696 te konbine avèk Medikaman tansyon wo Novartis a (Diovan, non jenerik: valsartan) ak dwòg eksperimantal AHU-377 la.AHU377 bloke mekanis de peptides ki responsab pou bese tansyon.Diovan amelyore vazodilatasyon ak stimul kò a elimine sodyòm ak dlo.
